
Mariarosaria Valente

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/515359/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Rare PSAP Variants and Possible Interaction with GBA in REM Sleep Behavior Disorder. Journal of Parkinson's Disease, 2022, 12, 333-340.	1.5	3
2	Response to Letter to the Editor on the article "Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination― Clinical Neurology and Neurosurgery, 2022, 213, 107129.	0.6	0
3	Turning off the siren of the night: botulinum toxin for the treatment of nocturnal groaning. A case series. Sleep Medicine, 2022, 92, 15-18.	0.8	0
4	Creutzfeldt-Jakob disease after COVID-19: infection-induced prion protein misfolding? A case report. Prion, 2022, 16, 78-83.	0.9	16
5	Guillain-Barré syndrome in the COVID-19 era: just an occasional cluster?. Journal of Neurology, 2021, 268, 1195-1197.	1.8	59
6	Reply to "Guillain‑Barré syndrome in the COVID‑19 era another occasional cluster?": Insights from two distinct clusters of Guillain–Barré syndrome detected in Europe in the COVID-19 era. Journal of Neurology, 2021, 268, 1201-1202.	1.8	5
7	Comprehensive Analysis of Familial Parkinsonism Genes in Rapidâ€Eyeâ€Movement Sleep Behavior Disorder. Movement Disorders, 2021, 36, 235-240.	2.2	11
8	Hyposmia and Dysgeusia in COVID-19. Neurology: Clinical Practice, 2021, 11, e92-e96.	0.8	4
9	Restless legs syndrome in internal medicine. , 2021, , .		1
10	Clinical and neurophysiological characterization of muscular weakness in severe COVID-19. Neurological Sciences, 2021, 42, 2173-2178.	0.9	31
11	Lower lymphocyte counts and older age are associated with reduced multiple sclerosis disease activity during dimethyl fumarate treatment. Multiple Sclerosis and Related Disorders, 2021, 49, 102781.	0.9	8
12	Epilepsy and episodic ataxia type 2: family study and review of the literature. Journal of Neurology, 2021, 268, 4296-4302.	1.8	14
13	Benign EEG variants in the sleep–wake cycle: A prospective observational study using the 10–20 system and additional electrodes. Neurophysiologie Clinique, 2021, 51, 233-242.	1.0	6
14	Seizures after Ischemic Stroke: A Matched Multicenter Study. Annals of Neurology, 2021, 90, 808-820.	2.8	54
15	Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination. Clinical Neurology and Neurosurgery, 2021, 208, 106839.	0.6	70
16	Novel Associations of <i>BST1</i> and <i>LAMP3</i> With REM Sleep Behavior Disorder. Neurology, 2021, 96, e1402-e1412.	1.5	12
17	The Emerging Role of Metabolism in Brain-Heart Axis: New Challenge for the Therapy and Prevention of Alzheimer Disease. May Thioredoxin Interacting Protein (TXNIP) Play a Role?. Biomolecules, 2021, 11, 1652.	1.8	6
18	Incidence of early poststroke seizures during reperfusion therapies in patients with acute ischemic stroke: An observational prospective study. Epilepsy and Behavior, 2020, 104, 106476.	0.9	26

MARIAROSARIA VALENTE

#	Article	IF	CITATIONS
19	Status epilepticus mimicking stroke recurrence. Epilepsy and Behavior, 2020, 104, 106509.	0.9	5
20	<i>GBA</i> variants in REM sleep behavior disorder. Neurology, 2020, 95, e1008-e1016.	1.5	45
21	Insomnia and daytime sleepiness predict 20-year mortality in older male adults: data from a population-based study. Sleep Medicine, 2020, 73, 202-207.	0.8	13
22	Fineâ€Mapping of <i>SNCA</i> in Rapid Eye Movement Sleep Behavior Disorder and Overt Synucleinopathies. Annals of Neurology, 2020, 87, 584-598.	2.8	39
23	SMPD1 variants do not have a major role in rapid eye movement sleep behavior disorder. Neurobiology of Aging, 2020, 93, 142.e5-142.e7.	1.5	4
24	Electrocardiographic RR Interval Dynamic Analysis to Identify Acute Stroke Patients at High Risk for Atrial Fibrillation Episodes During Stroke Unit Admission. Translational Stroke Research, 2019, 10, 273-278.	2.3	14
25	Advancing synthetic therapies for the treatment of restless legs syndrome. Expert Opinion on Pharmacotherapy, 2019, 20, 1971-1980.	0.9	8
26	ADMA as a possible marker of endothelial damage. A study in young asymptomatic patients with cerebral small vessel disease. Scientific Reports, 2019, 9, 14207.	1.6	24
27	Seizures Do Not Affect Disability and Mortality Outcomes of Stroke: A Population-Based Study. Journal of Clinical Medicine, 2019, 8, 2006.	1.0	12
28	Pharmacokinetic and pharmacodynamic considerations for the clinical efficacy of perampanel in focal onset seizures. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 93-102.	1.5	16
29	Prediction of late seizures after ischaemic stroke with a novel prognostic model (the SeLECT score): a multivariable prediction model development and validation study. Lancet Neurology, The, 2018, 17, 143-152.	4.9	178
30	A case of rapidly progressive dementia: Whipple disease of CNS. Neurological Sciences, 2018, 39, 591-592.	0.9	5
31	Pre-Procedural Statin Use Is Associated with Improved Long-Term Survival and Reduced Major Cardiovascular Events in Patients Undergoing Carotid Artery Stenting: A Retrospective Study. Journal of Clinical Medicine, 2018, 7, 286.	1.0	6
32	Pharmacokinetic drug evaluation of lacosamide for the treatment of partial-onset seizures. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 997-1005.	1.5	17
33	Intractable restless legs syndrome: role of prolonged-release oxycodone–naloxone. Neuropsychiatric Disease and Treatment, 2016, 12, 417.	1.0	6
34	Opioids in the treatment of restless legs syndrome: pharmacological and clinical aspects. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1035-1045.	1.5	7
35	Polysomnographic Sleep Patterns in Children and Adolescents in Unresponsive Wakefulness Syndrome. Journal of Head Trauma Rehabilitation, 2015, 30, 334-346.	1.0	25
36	Identification of Stroke Etiology May Contribute to Improve the Outcome in Dedicated Units. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, 802-810.	0.7	8

#	Article	IF	CITATIONS
37	Are Early Seizures Predictive of Epilepsy after a Stroke? Results of a Population-Based Study. Neuroepidemiology, 2015, 45, 50-58.	1.1	66
38	ADMET considerations when prescribing novel therapeutics to treat restless legs syndrome. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 1365-1380.	1.5	9
39	The contribution of assessing cognitive impairment in radiologically-isolated syndrome (RIS): a single case report follow-up study. Multiple Sclerosis Journal, 2014, 20, 1912-1915.	1.4	8
40	The importance of polysomnography in the evaluation of prolonged disorders of consciousness: sleep recordings more adequately correlate than stimulus-related evoked potentials with patients' clinical status. Sleep Medicine, 2014, 15, 393-400.	0.8	57
41	Investigational approaches to therapies for restless legs syndrome. Expert Opinion on Investigational Drugs, 2014, 23, 847-856.	1.9	3
42	Lacosamide for the treatment of epilepsy. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 459-468.	1.5	24
43	Restless Legs Syndrome in Internal Medicine. , 2013, , 141-147.		0
44	Should the definition of "sleep hygiene―be antedated of a century? A historical note based on an old book by Paolo Mantegazza, rediscovered. Neurological Sciences, 2013, 34, 755-760.	0.9	8
45	Stroke Incidence and 30-Day and Six-Month Case Fatality Rates in Udine, Italy: A Population-Based Prospective Study. International Journal of Stroke, 2013, 8, 100-105.	2.9	35
46	Restless legs syndrome in dialysis patients: a comparison between hemodialysis and continuous ambulatory peritoneal dialysis. Neurological Sciences, 2012, 33, 1311-1318.	0.9	24
47	Rem sleep brady-arrhythmias: An indication to pacemaker implantation?. Sleep Medicine, 2012, 13, 759-762.	0.8	14
48	ADMET considerations for restless leg syndrome drug treatments. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 1247-1261.	1.5	6
49	Incidence of Transient Ischemic Attack and Early Stroke Risk. Stroke, 2011, 42, 2751-2757.	1.0	59
50	The use of rotigotine in the treatment of restless legs syndrome. Therapeutic Advances in Neurological Disorders, 2010, 3, 241-248.	1.5	11
51	A caseâ€control study on restless legs syndrome in nondialyzed patients with chronic renal failure. Movement Disorders, 2010, 25, 1019-1025.	2.2	51
52	Pharmacotherapy of Restless Legs Syndrome with Pramipexole. Clinical Medicine Insights Therapeutics, 2010, 2, CMT.S3580.	0.4	0
53	Effects of Restless Legs Syndrome on Quality of Life and Psychological Status in Patients With Type 2 Diabetes. The Diabetes Educator, 2010, 36, 79-87.	2.6	28
54	Daytime sleepiness is associated with dementia and cognitive decline in older Italian adults: A population-based study. Sleep Medicine, 2010, 11, 372-377.	0.8	155

MARIAROSARIA VALENTE

#	Article	IF	CITATIONS
55	Restless legs syndrome: differential diagnosis and management with rotigotine. Neuropsychiatric Disease and Treatment, 2009, 5, 67.	1.0	17
56	Drugs with anticholinergic properties: cognitive and neuropsychiatric side-effects in elderly patients. Neurological Sciences, 2009, 30, 87-92.	0.9	93
57	Prevalence of â€~poor sleep' among patients with multiple sclerosis: An independent predictor of mental and physical status. Sleep Medicine, 2009, 10, 26-34.	0.8	171
58	Drugs with anticholinergic properties: a potential risk factor for psychosis onset in Alzheimer's disease?. Expert Opinion on Drug Safety, 2009, 8, 549-557.	1.0	15
59	Gabapentin enacarbil, a gabapentin prodrug for the treatment of the neurological symptoms associated with disorders such as restless legs syndrome. Current Opinion in Investigational Drugs, 2009, 10, 91-102.	2.3	8
60	Sarcoidosis as risk factor for cryptococcal meningitis in an apparently immunocompetent patient. Neurological Sciences, 2008, 29, 33-35.	0.9	19
61	Association of body rolling, leg rolling, and rhythmic feet movements in a young adult: A videoâ€polysomnographic study performed before and after one night of clonazepam. Movement Disorders, 2008, 23, 602-607.	2.2	16
62	Drugs with Anticholinergic Properties as a Risk Factor for Psychosis in Patients Affected by Alzheimer's Disease. Clinical Pharmacology and Therapeutics, 2008, 84, 63-68.	2.3	42
63	Clinical experience with pramipexole in the treatment of restless legs syndrome. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 225-235.	1.5	11
64	Drugs With Anticholinergic Properties as a Risk Factor for Cognitive Impairment in Elderly People. Journal of Clinical Psychopharmacology, 2008, 28, 654-659.	0.7	62
65	Sleep disturbances in dialysis patients. Journal of Nephrology, 2008, 21 Suppl 13, S66-70.	0.9	16
66	Association of Restless Legs Syndrome in Type 2 Diabetes: A Case-Control Study. Sleep, 2007, 30, 866-871.	0.6	137
67	Seizures With Prolonged EEG Abnormalities During an Attack of Migraine Without Aura. Headache, 2007, 47, 919-922.	1.8	11
68	Restless legs syndrome: diagnosis, epidemiology, classification and consequences. Neurological Sciences, 2007, 28, S37-S46.	0.9	47
69	Sensory Gating Deficit Assessed by P50/Pb Middle Latency Event Related Potential in Alzheimer's Disease. Journal of Clinical Neurophysiology, 2006, 23, 421-425.	0.9	51
70	Sleep disorders in patients with end-stage renal disease undergoing dialysis therapy. Nephrology Dialysis Transplantation, 2006, 21, 184-190.	0.4	243
71	The Acute Effect of a Low Dosage of Pramipexole on Severe Idiopathic Restless Legs Syndrome: An Open-Label Trial. Neuropsychobiology, 2006, 54, 195-200.	0.9	14
72	Changes in hemodynamics during isoflurane and propofol anesthesia: a comparison study. Neurological Research, 2005, 27, 433-435.	0.6	13

5

#	Article	IF	CITATIONS
73	Restless legs syndrome in end-stage renal disease. Sleep Medicine, 2004, 5, 309-315.	0.8	206
74	Sleep organization pattern as a prognostic marker at the subacute stage of post-traumatic coma. Clinical Neurophysiology, 2002, 113, 1798-1805.	0.7	111
75	Sleep and sleep deprivation as EEG activating methods. Clinical Neurophysiology, 2000, 111, S47-S53.	0.7	19
76	Sleep and EEG interictal epileptiform abnormalities in partial epilepsy. Clinical Neurophysiology, 2000, 111, S60-S64.	0.7	12
77	Evoked Potentials Suggest Cranial Nerves and CNS Involvement in Chronic Relapsing Polyradiculoneuropathy. European Neurology, 1989, 29, 145-149.	0.6	8
78	Sleep Disturbances Among Dialysis Patients. , 0, , .		0